Lale ÖCAL, Mehmet Salih SEVDİ, Sibel ZARALI, Murat İNANÇ, Murat BEKTAŞ, Ahmet GÜL, Burak İNCE, Nevzat KOCA, Besim Fazıl AĞARGÜN, Damla Yenersu GÜZEY, Ayşe İNCE, Yasemin YALÇINKAYA, Bahar ARTIM ESEN

A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic

Background/aim: COVID-19 pandemic created concerns among patients receiving immunosuppressive therapy. Frequency of COVID-19 and impact of lockdown on treatment compliance in patients with vasculitis are largely unknown. Materials and method: Patients with ANCA-associated and large vessel vasculitis that have been followed-up in our clinic were contacted by phone and a questionnaire containing home isolation status, treatment adherence and history of COVID-19 between March 1st and June 30th, 2020 was applied. Results: The survey was applied to 103 patients (F/M: 59/44, mean age: 53.2±12.5). Thirty-three (32%) patients didn’t attend at least one appointment; 98(95.1%) noted that they spent 3 months in home isolation. Five patients (4.8%) received immunosuppressives irregularly and 3(2.9%) developed symptoms due to undertreatment. Four (3.9%) patients admitted to hospital with a suspicion of COVID-19, but none of them had positive PCR or suggestive findings by imaging. COVID-19 was diagnosed in a patient with granulomatosis with polyangiitis during hospitalization for disease flare and she died despite treatment. Conclusion: Frequency of COVID-19 was low in patients with vasculitis in our single center cohort. Although outpatient appointments were postponed in one-third of our patients, high compliance with treatment and isolation rules ensured patients with vasculitis overcome this period with minimal morbidity and mortality.Key words: COVID-19, ANCA-associated vasculitis, large vessel vasculitis, treatment adherence, compliance

PDF

___

1. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases 2020; 79,7: 859-866.
2. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Annals of the Rheumatic Diseases 2020; 79(5): 667-668.
3. Seyahi E, Poyraz BC, Sut N, Akdogan S, Hamuryudan V. The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey. Rheumatology International 2020; 40(8): 1229-1238.
4. Chasseur P, Blockmans D, Von Frenckell C, Nicolas JB, Regniers C et al. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-associated vasculitis in a Belgian multicenter cohort. Acta Clinica Belgica 2020; 75(3): 163-169.
5. Tomelleri A, Sartorelli S, Campochiaro C, Baldissera EM, Dagna L. Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. Annals of the Rheumatic Diseases 2020; 79(9): 1252-1253.
6. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395(10234): 1417-1418.